Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$9.0K-98.18%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Charles Jahr
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Beta
- 0.75
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -41.27
Financials
Revenue
$9.0K-98.2%Net Income
$-20.32MEBITDA
$-20.28MFree Cash Flow
$-21.99MEPS (diluted)
$-0.80Shares Outstanding (diluted)
25.48M+17472.4%Operating Expenses
$10.80MCash & Debt
$11.24MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.41M | $-62.42M | $-1.79 |
| 2024 | $0.00 | $-75.37M | $-4.06 |
| 2023 | $0.00 | $-58.98M | $-4.80 |
| 2022 | $0.00 | $-66.05M | $-6.23 |
| 2021 | $0.00 | $-53.16M | $-7.00 |
| 2020 | $0.00 | $-35.24M | $-13.47 |
| 2019 | $8.15M | $-34.52M | $-39.60 |
| 2018 | $3.09M | $-30.09M | $-194.80 |
| 2017 | $3.81M | $-38.85M | $-267.20 |
| 2016 | $2.98M | $-53.30M | $-587.20 |
| 2015 | $5.22M | $-47.39M | $-564.14 |
| 2014 | $9.05M | $-13.73M | $-1.05 |
Valuation
OTLKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (12)
- Newsglobenewswire.com·25d ago·Neutral
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference Video webcast now available here
View source ↗ - Newszacks.com·49d ago·Neutral
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
View source ↗ - Newsseekingalpha.com·52d ago·Positive
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·52d ago·Negative
Oncobiologics Q3 Earnings Call Highlights Oncobiologics NASDAQ: OTLK said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United States.
View source ↗ - Newszacks.com·53d ago·Negative
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates Outlook Therapeutics, Inc. (OTLK) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.44 per share a year ago.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used
View source ↗ - Newsbenzinga.com·53d ago·Neutral
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Outlook Therapeutics, Inc. (NASDAQ:OTLK) will release its third quarter earnings report before the opening bell on Friday, Aug. 14.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
…s Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying warrants to pu…
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shar
View source ↗ - Newszacks.com·56d ago·Neutral
OTLK Up More Than 300% in 3 Months: Here's What You Should Know Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.
View source ↗
Earnings
Fri, Dec 18(in 2 months)
Consensus estimate $-0.06 per share
Typical surprise -4.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.09 vs $-0.08miss
- Fri, May 15$-0.16 vs $-0.12miss
- Tue, Feb 17$-0.22 vs $-0.17miss
- Fri, Dec 19$-0.22 vs $-0.23beat
- Thu, Aug 14$-0.44 vs $-0.42miss
- Thu, May 15$-0.40 vs $-0.55beat
Estimates and results for OTLK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OTLK officers and directors.
- Bought
- $31.5m
- Sold
- $590k
20 trades
1 trade
- Jahr Robert Charlesbought
- Jahr Robert Charlesbought
- Kenyon Lawrence Abought
- Kenyon Lawrence Abought
- Sukhtian Ghiath M.bought
- Sukhtian Ghiath M.bought
- Sukhtian Faisal Ghiathbought
- Haddadin Yezan Muntherbought
79 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OTLK.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.